Paula Rambarat MD , Adam D. DeVore MD, MHS , Ankeet S. Bhatt MD, MBA, ScM , Larry A. Allen MD, MHS , Colleen K. McIlvennan PhD, DNP, ANP , Gad Cotter MD , Amrita Mukhopadhyay MD, MS , Tariq Ahmad MD, MPH , Faraz S. Ahmad MD, MS , Mitchell A. Psotka MD, PhD
{"title":"Failure to Launch","authors":"Paula Rambarat MD , Adam D. DeVore MD, MHS , Ankeet S. Bhatt MD, MBA, ScM , Larry A. Allen MD, MHS , Colleen K. McIlvennan PhD, DNP, ANP , Gad Cotter MD , Amrita Mukhopadhyay MD, MS , Tariq Ahmad MD, MPH , Faraz S. Ahmad MD, MS , Mitchell A. Psotka MD, PhD","doi":"10.1016/j.jchf.2025.02.023","DOIUrl":null,"url":null,"abstract":"<div><div>There is a pressing need to translate evidence for heart failure (HF) therapies into contemporary practice. Medications that improve HF morbidity and mortality remain underused because of complex barriers at multiple levels across the health care ecosystem. High-quality implementation trials demonstrate that specific interventions can increase prescription, intensification, and persistence of HF medication. However, evidence-based interventions have not been widely implemented across health care organizations in the United States. This review explores 5 key strategies—patient activation, audit and feedback, rapid intensive initiation of medical therapy, virtual care teams, and clinical decision support tools—and discusses barriers to their widespread adoption. Although some barriers are specific to an intervention, others stem from systemic limitations among health care organizations and the health policy landscape. Using lessons learned from recent trials, this review also highlights future investigations needed to address these barriers, encourages uptake of successful implementation strategies, and discusses common approaches that should be abandoned.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 6","pages":"Pages 887-900"},"PeriodicalIF":10.3000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Heart failure","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213177925003622","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
There is a pressing need to translate evidence for heart failure (HF) therapies into contemporary practice. Medications that improve HF morbidity and mortality remain underused because of complex barriers at multiple levels across the health care ecosystem. High-quality implementation trials demonstrate that specific interventions can increase prescription, intensification, and persistence of HF medication. However, evidence-based interventions have not been widely implemented across health care organizations in the United States. This review explores 5 key strategies—patient activation, audit and feedback, rapid intensive initiation of medical therapy, virtual care teams, and clinical decision support tools—and discusses barriers to their widespread adoption. Although some barriers are specific to an intervention, others stem from systemic limitations among health care organizations and the health policy landscape. Using lessons learned from recent trials, this review also highlights future investigations needed to address these barriers, encourages uptake of successful implementation strategies, and discusses common approaches that should be abandoned.
期刊介绍:
JACC: Heart Failure publishes crucial findings on the pathophysiology, diagnosis, treatment, and care of heart failure patients. The goal is to enhance understanding through timely scientific communication on disease, clinical trials, outcomes, and therapeutic advances. The Journal fosters interdisciplinary connections with neuroscience, pulmonary medicine, nephrology, electrophysiology, and surgery related to heart failure. It also covers articles on pharmacogenetics, biomarkers, and metabolomics.